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ABSTRACT:
Prostate cancer is the second leading cause of cancer mortality in men in developed 
countries. Due to the heterogeneous nature of the disease, design of novel 
personalized treatments is required to achieve efﬁ  cient therapeutic responses. We 
have recently identiﬁ   ed phospholipase 2 group VII (PLA2G7) as a potential drug target 
especially in ERG oncogene positive prostate cancers. Here, the expression proﬁ  le 
of PLA2G7 was studied in 1137 prostate cancer and 409 adjacent non-malignant 
prostate tissues using immunohistochemistry to validate its biomarker potential 
and putative association with disease progression. In order to reveal the molecular 
alterations induced by PLA2G7 impairment, lipidomic and gene expression proﬁ  ling 
was performed in response to PLA2G7 silencing in cultured prostate cancer cells. 
Moreover, the antineoplastic effect of statins combined with PLA2G7 impairment was 
studied in prostate cancer cells to evaluate the potential of repositioning of in vivo 
compatible drugs developed for other indications towards anti-cancer purposes. The 
results indicated that PLA2G7 is a cancer-selective biomarker in 50 % of prostate 
cancers and associates with aggressive disease. The alterations induced by PLA2G7 
silencing highlighted the potential of PLA2G7 inhibition as an anti-proliferative, pro-
apoptotic and anti-migratorial therapeutic approach in prostate cancer. Moreover, 
the anti-proliferative effect of PLA2G7 silencing was potentiated by lipid-lowering 
statins in prostate cancer cells. Taken together, our results support the potential of 
PLA2G7 as a biomarker and a drug target in prostate cancer and present a rationale for 
combining PLA2G7 inhibition with the use of statins in prostate cancer management.
INTRODUCTION
Although prostate cancer is the most commonly 
diagnosed malignancy and the second most common cause 
of cancer mortality in men in developed countries [1], there 
is a prevailing lack of efﬁ  cient targeted and personalized 
therapeutic approaches. Given the heterogeneous nature 
and the complexity of molecular pathways in prostate 
cancer, combining different therapies may be a necessary 
step towards signiﬁ  cant therapeutic progress.
Approximately half of prostate cancer samples 
harbor an oncogenic gene fusion combining androgen Oncotarget 2011; 2:   1176 - 1190 1177 www.impactjournals.com/oncotarget
regulated transmembrane protease serine 2 (TMPRSS2) 
with oncogenic ETS transcription factors [2]. Ectopic 
expression of the most frequent fusion partner, ERG (v-ets 
erythroblastosis virus E26 oncogene homolog, avian), 
promotes multiple signaling pathways associated with 
cancer formation and progression [3-7]. However, ETS 
gene fusions are a challenge to target and ERG mediated 
oncogenic processes may be bypassed in advanced 
prostate cancer [8]. Therefore, novel more efﬁ  cient 
therapeutic approaches for this patient group, as well as 
for the early disease, would be of great importance. 
Phospholipase A2 group VII (PLA2G7) was recently 
found to be highly expressed especially in the tumors with 
high ERG expression [4, 9]. ERG was shown to induce 
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Figure 1: PLA2G7 is expressed in a cancer speciﬁ  c manner and associates with aggressive disease. (A) Staining intensity of 
PLA2G7 in primary prostate cancer (n = 1,137) and adjacent non-malignant prostate (n = 409) samples was scored as follows: Strong (+++), 
moderate (++), weak (+) or no staining (negative). Representative section of each staining intensity is presented. (B) Immunohistochemical 
staining results of PLA2G7 expression in adjacent non-malignant and cancer tissue samples for two patients are shown. The areas presented 
at higher magniﬁ  cation have been indicated in the core images. (C) The proportion of tissue samples with no staining and positive PLA2G7 
staining in non-malignant and cancer tissue samples included in the TMA. (D) The proportion of TMA tissue samples with no PLA2G7 
staining or positive PLA2G7 staining in non-malignant and cancer tissue samples according to Gleason score. The amount of samples in 
each group is indicated in parentheses. Signiﬁ  cant p-values between different histological stages are presented. (E) Kaplan-Meier curve 
presentation of prostate cancer speciﬁ  c survival in the patient groups with no PLA2G7 staining (n = 135) or positive PLA2G7 staining (n 
= 230) in the cancer samples.Oncotarget 2011; 2:   1176 - 1190 1178 www.impactjournals.com/oncotarget
the expression of PLA2G7, and knock-down of PLA2G7 
signiﬁ  cantly reduced the growth of ERG positive, but not 
ERG negative, prostate cancer cells in vitro, indicating 
potential as a biomarker and personalized drug target in 
ERG positive prostate cancers [9]. Furthermore, PLA2G7 
silencing was shown to sensitize prostate cancer cells to 
oxidative stress [9]. However, the molecular alterations in 
response to PLA2G7 expression in prostate cancer remain 
to be elucidated.
In contrast to cancer, the role and therapeutic 
potential of PLA2G7 has been under intensive research 
in the area of cardiovascular diseases. Although PLA2G7 
has been shown to exert anti-inﬂ  ammatory effects in a 
variety of experimental models, it also degrades apoptosis 
inducing oxidized phospholipids and simultaneously 
generates atherogenic inﬂ   ammatory products [10-12]. 
Accordingly, PLA2G7 mass and activity have been 
associated with an increased risk of cardiovascular 
diseases [13-16]. Interestingly, early results with PLA2G7 
inhibitor, darapladib, have been promising in the 
prevention and treatment of coronary heart disease [11, 
17]. In addition, lipid-lowering statins are known to reduce 
PLA2G7 mass and activity in plasma and atherosclerotic 
plaques [14, 18, 19].
The aim of this study is to validate PLA2G7 
as potential cancer selective biomarker, deepen our 
understanding on its molecular and cellular function 
and study the growth inhibitory potential of PLA2G7 
impairment combined with statin exposure in cultured 
prostate cancer cells. PLA2G7 expression was studied in 
a large set of non-malignant prostate and prostate cancer 
tissues using immunohistochemistry. In order to reveal 
the changes induced by PLA2G7 impairment in prostate 
cancer cells, lipidomic and gene expression proﬁ  ling 
was performed in cultured prostate cancer cells. The 
antineoplastic effect of statins combined with PLA2G7 
impairment was studied in prostate cancer cells to evaluate 
the potential for repositioning of in vivo compatible drugs 
developed for other indications towards anti-cancer 
purposes.
RESULTS
PLA2G7 is a potent biomarker distinguishing 
prostate cancer from non-malignant prostate 
tissues
Tissue microarray (TMA) containing samples from 
primary prostate tumors (n = 1137) along with adjacent 
normal tissues (n = 409) was utilized to study PLA2G7 
expression in prostate tissues. The samples were stained 
with previously validated PLA2G7 speciﬁ  c antibody, and 
the staining intensity was scored as presented in Figure 
1A [9]. The results conﬁ  rmed that PLA2G7 expression 
strongly associates with prostate cancer. PLA2G7 was 
expressed in 50.0 % of the primary prostate tumor samples, 
whereas only 2.7 % of the adjacent normal tissues showed 
any staining (Figure 1B-C and Supplemental Table S1). 
Importantly, the positive staining of PLA2G7 signiﬁ  cantly 
correlated with high (≥ 7) Gleason score (Figure 1D and 
Supplemental Table S1). In accordance to the association 
of PLA2G7 expression and higher Gleason score, the 
results from Kaplan-Meier analysis suggested that 
PLA2G7 positivity associates with poor survival and 
more aggressive disease (Figure 1E).
PLA2G7 silencing decreases the level of 
lysophosphatidylcholine
Supporting the key role of altered lipid metabolism 
in prostate carcinogenesis, westernized corn oil 
containing diet has been shown to enhance cancer 
progression in mice, whereas thiazolidinediones 
have been reported to inhibit prostate cancer cell 
growth in vitro and in vivo [20, 21]. In order to reveal 
the lipidomic changes induced by PLA2G7 impairment, 
cellular lipidomic proﬁ  les were analyzed in ERG positive 
VCaP prostate cancer cells expressing PLA2G7 at high 
levels (Figure 2A). Target gene silencing was conﬁ  rmed 
using qRT-PCR and western blot analysis (Figure 2B). 
Ultra Performance Liquid Chromatography - Mass 
Spectrometry (UPLC-MS) results indicate that the most 
prominent change in response to 48 h PLA2G7 silencing 
was a decrease in the cellular lysophosphatidylcholine 
(LPC, PC(16:0/0:0), 1-hexadecanoyl-sn-glycero-3-
phosphocholine) level (Figure 2C and Supplemental Table 
S2). This is in agreement with the known function of 
PLA2G7 in cardiovascular diseases and previous results 
with PLA2G7 inhibitor treatment showing signiﬁ  cant 
decrease in LPC levels in the arteries of pigs with induced 
diabetes and hypercholesterolemia [11].
PLA2G7 silencing induces apoptosis 
To get additional insights into the molecular 
mechanisms regulated by PLA2G7, genome-wide gene 
expression proﬁ  ling was performed in PLA2G7 impaired 
prostate cancer cells. Th    e results indicated that cell-to-
cell signaling and interaction, as well as cell death were 
the most signiﬁ   cantly enriched biological processes in 
response to PLA2G7 silencing (Table 1 and Supplemental 
Table S3). Induction of cell death, validated by measuring 
pro-apoptotic CASP8 and anti-apoptotic BCL2L1 mRNA 
expression (Figure 2D), is in accordance to our previous 
results, since PLA2G7 silencing was shown to induce 
caspase 3 and 7 activity in VCaP cells [9], indicating that 
PLA2G7 silencing activates both intrinsic and extrinsic 
apoptotic pathways.Oncotarget 2011; 2:   1176 - 1190 1179 www.impactjournals.com/oncotarget
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Figure 2: PLA2G7 silencing decreases the level of lysophosphatidylcholine, induces apoptosis and reduces prostate 
tumorigenesis. (A) PLA2G7 mRNA expression in cancerous and non-malignant prostate cell lines. (B) Validation of PLA2G7 gene 
silencing in VCaP prostate cancer cells at mRNA and protein level. (C) Heatmap presentation of the cellular lipidomic changes in response 
to PLA2G7 silencing in VCaP cells. The proﬁ  les were obtained at 48 h after transfection with two PLA2G7 siRNAs and compared to 
the respective scrambled siRNA control sample. The results are presented as the mean percentual change of two replicates in relation 
to the scrambled siRNA samples. Red color indicates upregulation and blue downregulation in response to PLA2G7 silencing. PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; SM, sphingomyelin, Cer, ceramide. (D) The effect of 
PLA2G7 silencing on the mRNA expression of pro-apoptotic CASP8 at 24 h and anti-apoptotic BCL2L1 at 24 h (left) and 48 h (right). (E) 
The effect of PLA2G7 silencing on the mRNA expression of ALDH1A1 at 24 h (left) and 48 h (right), and the relative ALDH activity at 48 
h. ALDH inhibitor DEAB was used as a positive control. Signiﬁ  cant p-values in comparison to scrambled control are indicated.Oncotarget 2011; 2:   1176 - 1190 1180 www.impactjournals.com/oncotarget
PLA2G7 silencing reduces tumorigenesis 
inducing aldehyde dehydrogenase activity
The presence of self-renewing and multi-potent 
cancer stem cells has been studied also in prostate cancer 
and signaling pathways implicated in the regulation of 
stem cell features such as neuroendocrine differentiation 
have been proposed as potential therapeutic targets in 
prostate cancer [22]. Interestingly, PLA2G7 silencing 
reduced the expression of aldehyde dehydrogenase 1A1 
(ALDH1A1) (Figure 2E), described as a prostate cancer 
stem cell marker and associated with poor prostate 
cancer outcome [23, 24]. Furthermore, PLA2G7 silencing 
reduced aldehyde dehydrogenase (ALDH) activity to the 
same level as ALDH inhibitor (Figure 2E). High ALDH 
activity has been reported to identify tumor-initiating as 
well as metastasis-initiating prostate cancer cells [25]. 
Taken together, these results support the association of 
PLA2G7 expression with aggressive disease and suggest 
that PLA2G7 promotes tumorigenesis and metastasis via 
inducing ALDH activity.
PLA2G7 silencing reduces cell adhesion and 
motility
The results from the genome-wide gene expression 
proﬁ   ling indicated that cell motility and invasion 
related canonical pathways were among the top altered 
processes in response to PLA2G7 silencing (Table 1 
and Supplemental Table S3). Furthermore, the most 
outstanding change in the gene expression proﬁ  le 48 h 
after  PLA2G7 knock-down was the increased mRNA 
24 h
Molecular and Cellular Functions n a p-value
Cell Cycle 28 5.53E-07 -2.08E-02
Cell-To-Cell Signaling and Interaction 26 2.37E-05 -1.92E-02
Cellular Development 19 3.77E-05 -1.96E-02
Cell Morphology 20 3.92E-05 -2.08E-02
Cell Death 41 7.98E-05 -2.08E-02
Canonical Pathways n a p-value
Rac Signaling 6 0.000353
TNFR1 Signaling 4 0.000805
Ephrin Receptor Signaling 7 0.00089
PAK Signaling 5 0.0012
Induction of Apoptosis by HIV1 4 0.00189
48 h
Molecular and Cellular Functions n a p-value
Cell-To-Cell Signaling and Interaction 16 1.52E-05 -1.56E-02
Cell Death 24 2.00E-05 -1.56E-02
Cellular Assembly and Organization 17 1.10E-04 -1.17E-02
Cellular Function and Maintenance 13 1.10E-04 -1.47E-02
Cellular Compromise 6 1.51E-04 -1.17E-02
Canonical Pathways n a p-value
Integrin Signaling 5 0.000974
Valine. Leucineand Isoleucine Biosynthesis 2 0.00115
Estrogen Receptor Signaling 4 0.0016
Huntington's Disease Signaling 5 0.00191
Glucocorticoid Receptor Signaling 5 0.00323
a The number of genes (up and down) regulated due to PLA2G7silencing.
Table 1: The effect of PLA2G7 silencing on VCaP gene expression proﬁ  le. The functional gene ontology and pathway 
annotations were analyzed for the sets of differentially expressed genes (logFC > 0.4 or < -0.4; FC > 1.32 or < 0.76) using Ingenuity 
Pathway Analysis Software.Oncotarget 2011; 2:   1176 - 1190 1181 www.impactjournals.com/oncotarget
expression of γ-actin (ACTG1, FC 3.84), suggesting 
possible dysregulation in F-actin polymerization. The 
altered mRNA expression of genes involved in cell 
adhesion (DSCAM, ITGB1, NCAM1), migration (ACTR3, 
CDC42, LIMK1) and metastasis (STAT3) as well as 
protein levels of PAK, pPAK and pSTAT3 were validated 
(Figure 3A-D). Supporting the putative role of PLA2G7 
in migration and metastasis, F-actin staining of VCaP 
cells stimulated with LPC showed a clear decrease in the 
amount of cell protrusions after PLA2G7 knock-down 
compared to scrambled siRNA treated cells (Figure 3E).
To validate the adhesion phenotype, cell attachment 
on  ﬁ   bronectin was monitored. The results indicated 
a signiﬁ   cant acceleration in the adherence of cells to 
ﬁ   bronectin in response to PLA2G7  silencing (Figure 
4A), mimicking the previously described ERG knock-
down phenotype [3], and supporting the possibility that 
PLA2G7 is an important mediator of ERG oncogene in 
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Figure 3: PLA2G7 affects the expression of multiple genes associated with cell adhesion and migration. (A) The change in 
the relative mRNA expression of ACTR3, CDC42, DSCAM, LIMK1, NCAM1,  and  STAT3 in response to 24 h siRNA transfection. (B) The 
effect of 48 h PLA2G7 silencing on ITGB mRNA expression. (C) The change in pSTAT3, pPAK and PAK protein expression in response to 
72 h PLA2G7 silencing. β-actin is presented as an endogenous control. (D) Schematic illustration of the Rac1 and CDC42 signaling related 
gene products as a pathway. Blue color indicates downregulation and red upregulation in response to PLA2G7 silencing. (E) Microscopic 
images (63 x) of PLA2G7 siRNA and scrambled siRNA transfected and LPC stimulated VCaP cells stained with phalloidin (F-actin, green; 
DAPI, blue) are shown. Arrows indicate the presence of cell protrusions.Oncotarget 2011; 2:   1176 - 1190 1182 www.impactjournals.com/oncotarget
prostate cancer. Since VCaP cells do not migrate in wound 
healing experiment nor grow in 3D matrix [26], PC-3 cells, 
expressing PLA2G7 (Figure 2A), were selected as a model 
to validate the functional effect of PLA2G7 silencing on 
prostate cancer cell motility and invasion. Interestingly, 
as previously seen in LNCaP cells [9], PLA2G7 silencing 
did not affect PC-3 cell viability (Figure 4B). However, 
the migratory capacity of PC-3 cells both in 2D and 3D 
cultures was decreased (Figure 4C-D) conﬁ  rming the role 
of PLA2G7 in promoting prostate cancer cell migration 
and invasion.
Statins potentiate the antiproliferative effect of 
PLA2G7 inhibition
Since statins are known to inhibit PLA2G7 in 
atherosclerotic plaques [19], their ability to reduce 
PLA2G7 expression and activity in VCaP prostate cancer 
cells was elucidated. However, although epidemiologic 
evidence supports the possible chemopreventive potential 
of statins in prostate cancer, previous studies with cultured 
prostate cancer cells have revealed that long exposure 
time (ad 5d) and micromolar concentrations of statins are 
needed to reduce cell growth in vitro [27-30].
The results from this study indicated that although 
PLA2G7 protein levels were not consistently affected by 
statins, the enzymatic activity of PLA2G7 was reduced 
by all four statins studied (Figure 5A-B). Furthermore, 
simvastatin,  ﬂ   uvastatin and lovastatin were able to 
inhibit PLA2G7 enzymatic activity synergistically with 
PLA2G7 siRNA. Due to these results connecting statins 
with PLA2G7 function also in prostate cancer, the effect 
of statins in combination with PLA2G7 knock-down on 
VCaP cell viability was analyzed. Interestingly, even 
though the changes in cell viability were studied already 
after 48 h combinatorial treatment, the results indicated 
that statins synergistically reinforced the anti-proliferative 
effect of PLA2G7 silencing (Figure 5C). 
DISCUSSION
In this study, we elucidated the potential of PLA2G7 
as a biomarker and therapeutic drug target in prostate 
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cancer management. By determining the expression 
level of PLA2G7 in malignant and healthy prostate 
samples from 453 prostate cancer patients, the biomarker 
potential of PLA2G7 and the size of the potential patient 
group beneﬁ  ting from PLA2G7 inhibition therapy, was 
evaluated. The cellular responses to PLA2G7 inhibition 
were studied to understand the PLA2G7 driven biological 
and oncogenic processes in prostate cancer cells. 
Furthermore, as combinatorial therapeutic approaches 
may be required to obtain signiﬁ  cant therapeutic progress, 
the ability of statins to potentiate the anti-proliferative 
effect of PLA2G7 impairment in prostate cancer cells was 
investigated.
Immunohistochemical staining results indicated that 
PLA2G7 is a potential prostate cancer biomarker present 
in approximately 50 percent of tumors in our cohort, and 
associating with high grade prostate tumors. Moreover, 
PLA2G7 impairment reduced aldehyde dehydrogenase 
activity, considered as a marker of prostate cancer stem 
cells as well as tumor- and metastasis-initiating prostate 
cancer cells [23-25] supporting the possibility that 
PLA2G7 expression may have prognostic signiﬁ  cance. 
This hypothesis is further supported by our previous 
results demonstrating PLA2G7 protein expression in 
70 % of metastatic prostate tumors compared to the 50 
% positivity observed in the primary tumors [9]. Since 
PLA2G7 is induced by ERG and is highly expressed 
especially in the ERG positive prostate cancers, it is a 
putative biomarker for this subgroup of prostate cancers 
[4, 9]. The antiproliferative and pro-apoptotic effect 
of PLA2G7 impairment was seen in the ERG positive 
prostate cancer cells, indicating that ERG positive 
prostate cancer cells are dependent on PLA2G7 function 
[9]. However, PLA2G7 positivity is not restricted to ERG 
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cancer cell viability. (A) The effect of 48 h statin (10 μM) treatments on PLA2G7 protein expression in VCaP cells. The relative 
PLA2G7 (PLA2G7/β-actin) protein expression has been indicated with bars. (B) The effect of 10 μM statins alone and in combination 
with PLA2G7 silencing on PLA2G7 activity in VCaP cells. Signiﬁ  cant p-values for individual treatments are given, compared with the 
scrambled control and diluent treated cells. (C) The relative effect of ﬂ  uvastatin, lovastatin, pravastatin and simvastatin in combination with 
PLA2G7 silencing on VCaP cell viability. Cell viability in diluent treated cells (scrambled and PLA2G7 siRNA transfected samples) was 
set as 100 % to distinguish the synergism detected. Signiﬁ  cant p-values for individual treatments are given, compared with the scrambled 
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positive cancer cells since other oncogenic mutations have 
been recently shown to induce PLA2G7 expression [31].
PLA2G7 impairment modulated the levels of multiple 
lipids in prostate cancer cells, the most striking being the 
reduction in lysophosphatidylcholine (LPC). In addition 
to promoting cardiovascular diseases, LPC is known to 
increase the expression of cell-to-cell adhesion molecules 
on endothelial cells and to induce the migration and 
proliferation of smooth muscle cells [32, 33]. Furthermore, 
LPC has been linked to cancer cell migration and metastasis 
via promoting invadopodia formation in multiple cancer 
cell lines as well as migration of PC-3 prostate cancer 
cells [34, 35]. Our results support a similar role for LPC 
in prostate cancer cells since PLA2G7 silencing followed 
by reduced LPC levels resulted in changes in multiple 
adhesion molecules, such as decrease in the expression 
of cell-to-cell adhesion molecules NCAM1 and DSCAM, 
and increase in extracellular matrix binding ITGB1. In 
addition to accelerated adhesion to ﬁ  bronectin, PLA2G7
silencing reduced cell migration and invasion in prostate 
cancer cell culture models. Furthermore, Rac1, CDC42 
and STAT3 signaling, known to promote invadopodia 
formation and metastasis, were reduced by PLA2G7 
impairment [36, 37]. STAT3 is also known to promote 
androgen-independent growth in cultured prostate cancer 
cells [38], giving additional support to the beneﬁ  cial effect 
of PLA2G7 inhibition in prostate cancer management. The 
anti-migratory effect was not restricted to ERG positive 
prostate cancer cells supporting the rationale of PLA2G7 
inhibition in the prevention and treatment of aggressive 
and metastatic tumors. Interestingly, PLA2G7 silencing 
was recently shown to reduce xenograft growth of colon 
cells expressing mutant p53 and activated Ras [31], 
indicating that in addition to prostate cancers, PLA2G7 
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Figure 6: Schematic ﬁ  gure showing the putative potential of PLA2G7 impairment in prostate cancer management. 
PLA2G7 expression and enzymatic function can be activated by e.g. ERG oncogene, inﬂ  ammation or by substrates produced by oxidative 
stress [9, 43]. Our results suggest that PLA2G7 is a potential novel prognostic and therapeutic biomarker associating with aggressive 
disease. Therapeutic intervention impairing the expression or function of PLA2G7 induces multiple antineoplastic effects in cultured 
prostate cancer cells. PLA2G7 inhibition sensitizes prostate cancer cells to oxidative stress induced damage, decreases tumorigenetic 
potential and proliferation, as well as induces apoptosis and inhibits cancer cell migration. Moreover, clinically widely used statins inhibit 
the enzymatic activity of PLA2G7 and synergistically inhibit prostate cancer cell viability with RNAi induced PLA2G7 inhibition.Oncotarget 2011; 2:   1176 - 1190 1185 www.impactjournals.com/oncotarget
may have potential as a drug target in other cancer types 
as well. 
In melanoma cells heat shock protein 90 (HSP90) 
inhibitors have been suggested to exert part of their 
antineoplastic effects by modulating phospholipase 
activity and related metabolic changes [39]. Furthermore, 
in cardiovascular diseases widely used and clinically well 
tolerated lipid-lowering statins are known to exert part 
of their beneﬁ   cial effects via PLA2G7 inhibition [14, 
18, 19]. This knowledge in combination with frequent 
expression and vital function of PLA2G7 in ERG positive 
prostate cancer cells provides a signiﬁ  cant opportunity for 
drug repositioning. Epidemiologic evidence supports the 
possible chemopreventive potential of statins especially in 
advanced prostate cancer, and recently statins have been 
associated with better outcomes among men receiving 
radiotherapy for prostate cancer [27, 28, 40, 41]. Statins 
decrease androgen receptor protein expression and induce 
apoptosis and cell growth arrest in cultured prostate 
cancer cells, and suppress tumor growth in prostate cancer 
mice xenografts [29, 30, 42]. Here we show for the ﬁ  rst 
time that statins reduce the enzymatic activity of PLA2G7 
in prostate cancer cells. Furthermore, a synergistic 
anti-proliferative effect was observed in response to 
combinatorial treatment with PLA2G7 inhibition and 
statins in cultured prostate cancer cells.
In conclusion, we propose PLA2G7 as a prognostic 
and theranostic biomarker, as well as a putative therapeutic 
target in prostate cancer (Figure 6). PLA2G7 promotes 
several oncogenic processes such as cell viability, 
migration and invasion in prostate cancer. Moreover, this 
is the ﬁ  rst study connecting statin treatment with reduced 
PLA2G7 activity in prostate cancer cells, and presents a 
rationale for combining PLA2G7 inhibition with statins in 
prostate cancer management. 
METHODS
Clinical prostate cancer samples
Samples from 453 prostate cancer patients treated 
with total prostatectomy between the years 1982 and 1998 
at the Helsinki University Central Hospital, Finland, were 
included in this study. The allowance was obtained from 
the local ethical committee and all tissue samples were 
acquired and used according to contemporary regulatory 
guidelines. Median age of the patients at diagnosis was 
63 (44 – 83) years. None of the patients had received 
adjuvant therapy before or immediately after the surgery. 
Histopathological features were re-viewed using the 
corresponding haematoxylin and eosin or herovici stained 
slides by two experienced pathologists (A.S. and S.N.), 
and clinical follow-up information was collected from 
patient  ﬁ   les. Median tumour area (the percentage of 
tumour in all patient’s histological sections) was 15 %, 
ranging from 1 % to 100 %, and the median post-surgery 
follow-up time was 13.3 (11.3 – 25.0) years.
Immunohistochemistry and statistical analysis of 
stainings
Tissue microarray (TMA) blocks were constructed 
using archival formalin-ﬁ  xed parafﬁ  n-embedded (FFPE) 
prostatectomy blocks. Recipient blocks were predrilled 
with an automated TMA instrument (TMA Master, 3D 
Histech) and donor block cores (Ø 1.0 mm) were punched 
manually (Tissue-Tek® Quick-RayTM, Sakura Finetek). 
The TMA blocks consisted of four samples from each 
patient; two tissue cores from the area containing the most 
dominant Gleason grade pattern, one core out of the area 
with second most dominant Gleason grade pattern and one 
core from an adjacent benign glandular area. TMA blocks 
contained a total of 1,802 cores. All cancer cores were 
graded individually by experienced pathologists (A.S., 
S.N.) according to contemporary Gleason grading criteria. 
Freshly cut TMA sections mounted on electrically 
charged glass slides (SuperFrost® Plus, Menzel-
Gläser, Germany) were stained with a fully automatic 
immunohistochemical system Benchmark XT (Ventana 
Medical Systems, Illkirch, France) using a biotin-
free multimer-based detection system (ultraView™ 
Universal Red, Ventana Medical Systems). The slides 
were pre-treated with standard cell conditioning using 
CC1 buffer and incubated for 60 minutes with the rabbit 
polyclonal primary antibody (1:150, Cayman Chemical). 
Hematoxylin II and Bluing Reagent (Ventana Medical 
Systems) were used as counterstains. Experiment included 
normal salivary gland as an external positive control 
tissue. Negative controls were performed by replacing the 
primary antibody with corresponding rabbit IgG.
The TMA slides were digitized with an automated 
whole slide scanner (Mirax Scan, Zeiss, Göttingen, 
Germany), using a 20 x objective (numerical aperture 0.75) 
and a Sony DFW-X710 camera with a 1024 x 768 pixel 
CCD sensor (Sony Corporation, Tokyo, Japan). The pixel 
resolution was 0.26 μm. The images were compressed to 
a wavelet ﬁ  le format (Enhanced Compressed Wavelet, 
ECW, ER Mapper, Erdas Inc, Atlanta, Georgia) with a 
conservative compression ratio of 1:5. The compressed 
virtual slides were uploaded to a web server (http://
ﬁ  mm.webmicroscope.net) running image server software 
(Image Web Server, Erdas Inc, Atlanta, Georgia).
The expression of PLA2G7 was evaluated by 
the pathologists (A.S., S.N., T.M.) blinded to the 
clinicopathological data at the time of scoring. Disease 
speciﬁ  c survival was deﬁ  ned as the time from diagnosis 
to the time of death due to prostate cancer. Patients who 
died of intercurrent causes were censored. Survival curves 
were calculated according to Kaplan-Meier and patient Oncotarget 2011; 2:   1176 - 1190 1186 www.impactjournals.com/oncotarget
survival differences were analyzed using the log rank 
test. Gleason grading was available for 1,546 (85.8 %) of 
the 1,802 TMA cores stained with PLA2G7 antibody and 
survival information was sufﬁ  cient for 365 patients. In the 
survival analysis, a maximum score of each cancer cores 
of an individual patient was correlated with the clinical 
end-point.
Cell culture
VCaP prostate cancer cells were received from 
Kenneth Pienta (University of Michigan, MI) or 
purchased from American Type Culture Collection 
(LGC Promochem AB, Borås, Sweden), and PC-3 cells 
were purchased from American Type Culture Collection 
(LGC Promochem AB). Both cell lines were grown in 
RPMI-1640 medium (Invitrogen, Carlsbad, CA). LNCaP 
cells were received from Dr. Marco Cecchini (University 
of Bern, Switzerland) and EP156T from Dr. Varda Rotter 
(Weizmann Institute of Science,Rehovot, Israel). The 
22Rv1 cells were purchased from Deutsche Sammlung 
von Microorganismen und Zellkulturen GmbH (DSMZ, 
Braunschweig, Germany), RWPE-1 cells from American 
Type Culture Collection (LGC Promochem AB) and 
primary prostate epithelial cells (PrEc) from Lonza 
(Lonza Group Ltd, Basel, Switzerland). 
Fluvastatin, lovastatin, pravastatin and simvastatin 
were purchased from Tocris (Tocris Bioscience, Ellisville, 
MO). Fluvastatin and simvastatin were diluted in DMSO, 
lovastatin in ethanol and pravastatin in PBS.
Gene knock-down using RNA interference
Speciﬁ  c gene knock-downs using siRNA molecules 
(Qiagen  GmbH, Hilden, Germany) targeting PLA2G7 
(SI00072177, AAGGACTCTATTGATAGGGAA; 
SI00072184, TCCGTTGGTTGTACAGACTTA) were 
performed. AllStars Negative Control scrambled siRNA 
(Qiagen) was used as a negative control. The siRNAs 
were pipeted onto plates, followed by addition of the 
transfection agent (siLentFect Lipid Reagent, Bio-Rad 
Laboratories, Hercules, CA) and appropriate amount of 
cells. The PLA2G7 siRNAs were used either separately 
or as a pooled siRNA and the ﬁ  nal siRNA concentration 
was 13 nM.
Lipidomic proﬁ  ling
VCaP cells were transfected in two replicates with 
two separate PLA2G7 siRNAs as well as scrambled control 
siRNA. After 48 h the cells were detached and washed 
two times with cold PBS and cell pellets were frozen to 
-80 °C. The cell pellets were homogenized with 50 μl PBS 
by using 3 grinding balls (Ø 3 and 5 mm) with a Retsch 
mixer mill MM400 homogenizer at 20 Hz for 2 min. From 
the homogenate, 5 μl was taken for the protein assay and 
15 μl was used for lipid extraction (chloroform:methanol 
(2:1; 100 μl)) and spiked with an internal standard mixture 
of PC(17:0/0:0), MG(17:0/0:0/0:0)[rac], PG(17:0/17:0)
[rac], Cer(d18:1/17:0), PS(17:0/17:0), PC(17:0/17:0), 
PA(17:0/17:0), PE(17:0/17:0), DG(17:0/17:0/0:0)[rac] 
and TG(17:0/17:0/17:0) at concentration levels of 0.1-
0.2 μg / sample. The samples were vortexed for 2 min, 
incubated 30 min at RT and centrifuged at 7800 g for 3 
min.
After extraction, the lower phase (60 μl) was 
separated and spiked with the labelled internal standard 
mixture containing PC(16:1-D3/0:0), PC(16:1/16:1-D6) 
and TG(16:0/16:0/16:0-13C3) at concentration level 
of 0.1 μg/sample. Lipid extracts were analysed on a 
Waters Q-Tof Premier mass spectrometer combined with 
an Acquity Ultra Performance LCTM  (UPLCTM). The 
column used was an Acquity UPLCTM BEH C18 2.1 × 
100 mm with 1.7 μm particles. The solvent system was 
A) ultrapure water (1% 1 M NH4Ac, 0.1% HCOOH) and 
B) LC/MS grade acetonitrile/isopropanol (1:1, 1% 1M 
NH4Ac, 0.1% HCOOH) and the gradient started from 
65% A / 35% B, reached 80% B in 2 min, 100% B in 7 
min and remained there for 7 min. The ﬂ  ow rate was 0.400 
ml/min and the injected aliquot 2.0 μl (Acquity Sample 
Organizer, at 10 °C). Leucine enkephaline was used 
as the lock spray reference compounds. The data were 
collected at mass range of m/z 200-1,200 in negative ion 
mode with scan duration of 0.2 s. The data were processed 
using MZmine 2 software (http://mzmine.sourceforge.
net/) and the lipid identiﬁ  cation was based on an internal 
spectral library and tandem mass spectrometry. Protein 
content of the samples was determined from the PBS 
homogenate of the cells (5 μl) which was diluted further 
for Micro BCATM Protein Assay Kit (Pierce, Rockford, 
IL). Spectrophotometric determination was performed on 
a Multiskan EX instrument (Thermo Scientiﬁ  c, Vantaa, 
Finland), and the total protein content of the sample was 
used in the normalization of the data.
Gene expression analysis with bead-arrays
Total RNA was extracted using RNeasy (Qiagen) 
and integrity of the RNA was monitored using Bioanalyzer 
2100 (Agilent Technologies) according to manufacturer’s 
instructions. Puriﬁ  ed total RNA (500 ng) was ampliﬁ  ed 
with the TotalPrep Kit (Ambion, Austin, TX) and the biotin 
labeled cRNA was hybridized to Sentrix HumanRef-12 
Expression BeadChips (Illumina, San Diego, CA). 
The arrays were scanned with the BeadArray Reader 
(Illumina). The raw gene expression data were quantile-
normalized and analyzed with the R / Bioconductor 
software [44]. Statistical analysis of differential gene 
expression was performed using the empirical Bayes 
statistics implemented in the eBayes function of the Oncotarget 2011; 2:   1176 - 1190 1187 www.impactjournals.com/oncotarget
limma package [45]. Gene expression proﬁ   les of the 
PLA2G7 knock-down samples were compared to the 
respective control samples. The threshold for differential 
expression was q < 0.05 after the Benjamini-Hochberg 
multiple testing correction. The functional gene ontology 
and pathway annotations were analyzed for the sets of 
differentially expressed genes (logFC > 0.4 or < -0.4; 
FC > 1.32 or < 0.76) using Ingenuity Pathway Analysis 
Software (Ingenuity Systems Inc., Redwood City, CA, 
USA). Microarray data have been deposited in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress) 
under accession number E-TABM-1172.
TaqMan quantitative reverse transcriptase PCR
RNA samples extracted with RNeasy Mini Kit 
(Qiagen), were reversely transcripted to cDNA (High 
Capacity cDNA Reverse Transcription Kit, Applied 
Biosystems) and PCR reaction samples were analyzed in 
96-well or 384-well format. TaqMan quantitative reverse 
transcriptase PCR (qRT-PCR)  analysis (Finnish DNA 
Microarray Centre, Centre for Biotechnology, University 
of Turku) was performed using ABI Prism 7900 (Applied 
Biosystems) and quantitation was carried out using the 
ΔΔCT method with RQ manager 1.2 software (Applied 
Biosystems). At least two replicate samples were studied 
for detection of target mRNA expression and β-actin was 
used as an endogenous control. The primers and probes 
were designed and selected with the help of Universal 
ProbeLibrary Assay Design Center (Roche Diagnostics) 
(Supplemental Table S4).
Western blot analysis
Whole-cell lysates were prepared using lysis buffer 
(62.5 mM Tris, 1 % SDS, 5 %, β-mercaptoethanol 10 % 
glycerol, bromophenol blue). Antibodies used included, 
anti-pPAK (1:500, 2606S, Cell signaling technology, 
Danvers, MA), anti-PAK (1:1000, sc-881, Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-pSTAT3 (1:500, 
sc-7993, Santa Cruz Biotechnology) and anti-PLA2G7 
(1:500, Cayman Chemical) antibodies, as well as secondary 
ECL IgG HRP-linked (1:4000, Amersham Life Sciences, 
Fairﬁ  eld, CT) and Alexa Fluor (1:4000, Molecular Probes, 
Invitrogen) antibodies.  β-actin  (1:5000, antibody from 
Sigma) was used as a loading control. The probed proteins 
were detected using enhanced chemiluminescence system 
(Amersham Life Sciences) or Odyssey Infrared Imaging 
System (LI-COR Biosciences, Lincoln, NE) according 
to the manufacturer’s instructions. The obtained signals 
were densitometrically analyzed with GeneTools software 
(SynGene, Synoptics Ltd, Cambridge, UK).
Determination of aldehyde dehydrogenase 
(ALDH) activity
The activity of ALDH was determined with Aldeﬂ  uor 
reagent (Stemcell Technologies, Vancouver BC, Canada) 
according to manufacturer’s instructions. Cells (2,000 
/ well) were plated and transfected as described in 384-
well plates and incubated for 48 h. Medium was removed 
and cells washed with PBS, 10 μl of Aldeﬂ  uor (Stemcell 
Technologies, Vancouver BC, Canada) or Aldeﬂ  uor with 
DEAB (ALDH inhibitor diethylaminobenzaldehyde) 
was added to the cells and incubated at 37 °C for 30 
minutes. Solutions were removed, cells washed, and 20 
μl of assay buffer added into each well. The ﬂ  uorometric 
signal was determined with Envision Multilabel Reader 
(PerkinElmer, Massachusetts, MA).
Immunoﬂ  uorescence staining
For the immunoﬂ   uorescence staining, 10 μM 
lysophosphatidyl choline (LPC, 1-  hexadecanoyl-  sn-
glycerol-  3-  phosphorylcholine; Cayman Chemical, Ann 
Arbor, MI) was added to the siRNA transfected cells at 24 
h time point. Cells were ﬁ  xed at 72 h time point with 4 % 
paraformaldehyde (PFA) in PBS, permeabilized with 0.2 
% Triton X-100, and blocked with 3 % BSA / PBS. Cells 
were stained with Alexa conjugated Phalloidin (1:100, 
Molecular Probes, Invitrogen), nuclei with Vectashield 
mounting medium (Vector Laboratories, Burlingame, 
CA) containing DAPI and images were taken with Zeiss 
Axiovert 200M ﬂ  uorescence microscope (Carl Zeiss AG, 
Oberkochen, Germany).
Cell viability assay
Prostate cancer cells were transfected on a 384-well 
plate and cell viability determined with CellTiter-Glo cell 
viability assay (Promega) according to the manufacturer’s 
instructions. In compound-siRNA combinatorial cell 
viability assays a dilution series (10 pM – 10 μM) of 
statins were added to the cells 24 h after transfection and 
cell viability was determined following 48 h combinatorial 
treatment. The results were scanned with EnVision 
Multilabel platereader (PerkinElmer / Wallac). 
Cell adhesion assay
Plates (96 wells) were coated with ﬁ  bronectin (5 μg / 
ml; CalbioChem, San Diego, CA) and blocked with 0.1 % 
bovine serum albumin (BSA). VCaP cells were harvested 
72 hours after siRNA transfection and trypsin was 
inactivated with 0.2 % soybean trypsin inhibitor (Sigma). 
Cells were suspended in 0.5 % BSA in serum free RPMI, 
seeded (10000 / well) on the plates, and allowed to adhere Oncotarget 2011; 2:   1176 - 1190 1188 www.impactjournals.com/oncotarget
for 10, 20 and 30 minutes at 37 °C. After washing with 
PBS, cells were ﬁ  xed (4 % PFA, 10 minutes) and stained 
with propidium iodide (PI). The attached PI-stained 
cells were counted using Acumen Assay Explorer (TTP 
LabTech Ltd, Royston, UK).
Wound healing assay
PC-3 prostate cancer cells were transfected with 
siRNAs on 96-well plates (Essen ImageLock, Essen 
Instruments, UK). After 72 h transfection, when cells 
reached conﬂ   uency, a wound was scratched across 
each well (Wound Maker 96 Tool, Essen Instruments). 
Wound conﬂ  uence was monitored with Incucyte Live-
Cell Imaging System and software (Essen Instruments) 
and the amount of cell motility was determined at 6 h 
by comparing the mean relative wound density in each 
experiment.
3D cell culture
PC-3 cells were transfected with siRNAs 72 h prior 
to detaching cells from monolayer cultures. Uncoated 
Angiogenesis μ-slide (Ibidi Gmbh, Germany) wells were 
ﬁ  lled with 10 μl of Matrigel / culture medium (1:1; 50 
%) and polymerized at 37 °C for 1 h. Transfected cells 
(20,000 cells / ml density, ~ 1,000 cells / well) were plated 
on the slides and left to attach for 1–2 h at 37 °C before 
covering with a second layer of Matrigel / culture medium 
(1:4, 25 %). Matrigel was allowed to polymerize overnight 
at 37 °C. Cell culture medium was changed every second 
day. After 8 days the 3D cultures were incubated for 30 
min at 37 °C with Calcein AM live cell dye (Invitrogen). 
Confocal three-dimensional images were taken using 
Zeiss Axiovert 200 M with spinning disc confocal 
unit Yokogawa CSU22 and a Zeiss Plan-Neoﬂ  uar  5× 
objective. Z-stacks were acquired with a step-size of 19 
μm. Intensity projections were created using SlideBook 
4.2.0.7 and NIH ImageJ (http://rsbweb.nih.gov/ij/), and 
further analyzed with VTT Acca software (sensitivity 15; 
threshold 1, structures less than 40 pixels in area / size 
ﬁ  ltered out). Box plots were visualized with R.
PLA2G7 activity assay
VCaP cells were plated and transfected with siRNAs 
24 hours before addition of 10 μM statins. After 48 h of 
combinatorial treatment the samples were lysed, managed 
and analyzed with EnVision Multilabel platereader 
(PerkinElmer / Wallac) according to the instructions 
of PLA2G7 (PAF acetylhydrolase) activity assay 
manufacturer (Cayman Chemical).
Statistical analysis
The results are presented as the mean ± SD. 
Statistical analyses were performed using Student’s t-test 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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